Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma
- PMID: 11381372
- DOI: 10.1053/hupa.2001.24329
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma
Abstract
The distinction between pleural epithelial mesothelioma and peripheral lung adenocarcinoma involving the pleura is still an important diagnostic problem for surgical pathologists. The aim of our study was to identify the most specific and sensitive markers for the positive identification of mesothelioma to select a limited, appropriate panel of antibodies to differentiate between mesothelioma and adenocarcinoma. Forty-two cases of epithelial mesotheliomas and 23 cases of pulmonary adenocarcinomas were stained with the following antibodies: anticalretinin, antithrombomodulin, anti-CD44H, and monoclonal antibody HBME-1. We also studied the value of other markers in current use: cytokeratins AE1/AE3 and CAM5.2, epithelial membrane antigen (EMA), carcinoembryonic antigen (CEA), Ber-EP4, B72.3, and CD15. Of the mesotheliomas, 42 stained for calretinin, 39 (92.8%) for thrombomodulin, 42 stained for CD44H, and 41 (97.6%) stained for HBME-1. Among negative markers, 4 (9.5%) mesothelioma cases stained for CEA, 5 (11.9%) stained for Ber-EP4, 6 (14.2%) stained for B72.3, and 2 (4.7%) stained for CD15. Of the lung adenocarcinomas, 2 (8.7%) cases showed reactivity for calretinin, 5 (21.7%) for thrombomodulin, 13 (56.5%) for CD44H, all for HBME-1, 22 (95.6%) for CEA, 22 (95.6%) for Ber-EP4, 8 (34.7%) for B72.3, and all for CD15. In conclusion, calretinin and thrombomodulin were the most specific positive mesothelial markers, whereas CD44H and HBME-1 showed high sensitivity but very low specificity. Among negative markers, we advocate the use of CEA and CD15 which were the most specific in differentiating mesotheliomas from adenocarcinomas.
Similar articles
-
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.Pathol Int. 2007 Apr;57(4):190-9. doi: 10.1111/j.1440-1827.2007.02080.x. Pathol Int. 2007. PMID: 17316414
-
Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.Mod Pathol. 2000 Feb;13(2):107-12. doi: 10.1038/modpathol.3880018. Mod Pathol. 2000. PMID: 10697265
-
[A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].Pneumonol Alergol Pol. 2007;75(1):57-69. Pneumonol Alergol Pol. 2007. PMID: 17541913 Polish.
-
In search of a positive immunohistochemical marker for mesothelioma: an update.Adv Anat Pathol. 1998 Jan;5(1):53-60. Adv Anat Pathol. 1998. PMID: 9868512 Review. No abstract available.
-
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.Histopathology. 2006 Feb;48(3):223-32. doi: 10.1111/j.1365-2559.2005.02331.x. Histopathology. 2006. PMID: 16430468 Review.
Cited by
-
[Pseudo-mesotheliomatous adenocarcinoma of the lung].Pathologe. 2010 Jul;31(4):283-9. doi: 10.1007/s00292-009-1235-z. Pathologe. 2010. PMID: 19830430 German.
-
LTB4 is present in exudative pleural effusions and contributes actively to neutrophil recruitment in the inflamed pleural space.Clin Exp Immunol. 2004 Mar;135(3):519-27. doi: 10.1111/j.1365-2249.2003.02387.x. Clin Exp Immunol. 2004. PMID: 15008988 Free PMC article.
-
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.Cancer Immunol Immunother. 2018 Dec;67(12):1853-1862. doi: 10.1007/s00262-018-2236-7. Epub 2018 Sep 12. Cancer Immunol Immunother. 2018. PMID: 30209589 Free PMC article. Clinical Trial.
-
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.J Thorac Dis. 2013 Dec;5(6):E254-307. doi: 10.3978/j.issn.2072-1439.2013.11.28. J Thorac Dis. 2013. PMID: 24416529 Free PMC article. Review. No abstract available.
-
Diagnosis and prognosis of malignant mesothelioma of the tunica vaginalis testis.Can Urol Assoc J. 2012 Dec;6(6):E238-41. doi: 10.5489/cuaj.10200. Epub 2011 Sep 8. Can Urol Assoc J. 2012. PMID: 21914425 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous